Cogent Biosciences, Inc.
COGTHealthcareNASDAQBiotechnology · Last scanned May 28, 2026
Scan Results
Daily timeframe2 of 4 indicators bearish as of May 27
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Valued at $5.90B, COGT is a mid-cap name in its sector. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Market Cap
$5.90B
Beta
0.37
P/E (TTM)
—
P/E (Fwd)
-36.70
EPS (TTM)
$-2.17
EPS (Fwd)
$-0.94
ROE
-85.7%
ROA
-38.1%
Cash
$866.4M
Total Debt
$238.7M
Free CF
-$167.3M
52W Change
526.3%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $866.4M in cash comfortably exceeding the $238.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$167.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -85.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
COGT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, COGT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing COGT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.